Bill McKenzie, CEO
 
Bill brings over 30 years of industry experience to this role, building and driving highly successful new businesses within large corporations and small startups.
 
Prior to joining Shoreline Biome, Bill was a managing partner at Upstart Life Science, a management consulting firm that partners with visionary life science founders to help realize their dream of bringing transformative technologies to the world.
 
Bill honed his business skills at Millipore and PerkinElmer where he held both mid-manager and executive level positions. While there, he launched a number of highly successful new businesses in the molecular diagnostics, life science research, and medical device markets and has designed and negotiated numerous partnerships and acquisitions. Bill has served on a number of life science company boards and is currently a board member at seqWell, a next-gen sequencing company located in Beverly, MA. Bill was a board member at WaferGen BioSystems, a genomics company in Freemont, CA and was instrumental in its merger with Takara Bio in 2017. Bill also served on the board at Quad Technologies, a cell separations company, headquartered in Woburn, MA and acquired by Bio-Techne in 2018.
 
Bill has broad cultural background and experience having worked and lived in the US, Europe, India, China, Japan and Thailand.
 
Bill earned B.S. and M.S. degrees in biology from the University of Massachusetts, Boston.
 
Tom Jarvie, Co-Founder and Chief Marketing Officer
Tom built key research and development infrastructure as part of two biotech start-ups. With over 20 years of experience in biotech and over 15 years of experience bringing transformative next-generation sequencing products to market, he has a broad background in science and business. In addition to the design, set-up and operation of high-throughput bioscience laboratories, his experience includes commercial project management, product development and lifecycle management, market research and customer requirements development, sales and marketing, and customer support. He was the project leader at 454 Life Sciences for multiple product lines, including reagents, assays, and software for the 454 GS 20, GS FLX and GS Junior sequencers.
 
Tom received his Ph.D. in physical chemistry from the University of California, Berkeley and his B.S. in chemistry from The College of William and Mary.
 
Mark Driscoll, Co-Founder and Chief Science Officer
 
Mark has led and supported teams launching transformative new innovations globally at Molecular Stagings and 454 Life Sciences. In 2004, he led the development team at 454 Life Sciences that launched the GS 20, the first of the NGS (Next Generation Sequencing) systems, which revolutionized the world of DNA sequencing. He was part of the development teams that launched the GS FLX, the GS FLX+, and the GS Junior, the first of the benchtop sequencers. Mark has experience leading a development team consisting of subteams in hardware, software, informatics, reagents, marketing, and customer support.
 
Mark received his Ph.D. in biochemistry from the University of Rochester and his B.S. in biology from the University of Buffalo.
 
Karen Woodward, VP of Business Development
 
Karen developed and launched new genomic products in the microarray space at numerous Life Sciences companies including Packard BioChip, PerkinElmer and GeneXP Biosciences. She was part of and led strategic business development and partnership efforts at several genomic services laboratories including Beckman Coulter Genomics, Covance and Generation Health. Karen was instrumental in multimillion-dollar sales that lead to the 2009 acquisition of Cogenics by Beckman Coulter in 2009, as well as the successful commercialization and launch of Covance Genomics services after the acquisition of Merck’s Rosetta operation in Seattle.  After her time with Covance Genomics, Karen was VP of Strategic Operations and Account Management at Generation Health (acquired by CVS Caremark) and it’s spin-out MetaDiagnostic delivering molecular diagnostic test developers the key clinical utility, health outcome and cost effectiveness evidence data crucial to support their diagnostic test reimbursement by payers.  
 
Karen received her Ph.D. in molecular genetics and microbiology from the University of Massachusetts Medical School, Graduate School of Biomedical Sciences and her B.A. in biology from Clark University.
 

Dominique Carrillo, Manufacturing

Dominique worked as an engineer for the Davao City Water District in the Philippines designing processes and testing pilots for water treatment facilities. She came to the United States for graduate school while simultaneously working as a Lab Technician in an academic research lab performing microbial cloning experiments. She landed an internship with Shoreline Biome in the summer of 2018 and has been with the company ever since.

Dominique graduated with a B.S. in Chemical Engineering from the University of the Philippines and a M.S. in Microbial Systems Analysis from the University of Connecticut.

Christina Clark, Head of Manufacturing
 
Christina has worked in the biotech industry for the past 19 years donning many hats, with experience as a bench technician, quality control analyst, method development scientist, R&D scientist and finally as the manager of quality control and manufacturing.
She spent 13 years at 454 Life Science. In her first two years at Shoreline Biome, Christina was involved in product development, testing reagents, and processes. Currently, she is the head of quality control and manufacturing.
 
Chris received her Bachelor of Science degree from the University of Massachusetts, Amherst and and MS from the University of New Haven Cell in molecular biology.   
 
Dawn Gratalo, Group Lead of R&D
 
Dawn has been a member of R&D teams at Illumina and 454 Life Sciences, as well as several biotech startups. Dawn was instrumental in the development and commercialization of products across a range of technologies including microarrays, immunoassays, and Next Generation Sequencing.  While at 454 Life Sciences she was a member of the development team that launched the FLX+ and GS Junior Next Generation Sequencing Systems. She has built and led R&D teams from product concept to commercialization. Her experience in customer driven product development has led to successful launch of life science products in both small and large companies.
 
Dawn received a B.S in biology from Wilkes University and an M.S. in cellular and molecular biology from the University of New Haven.
 
Joe Tokarski, Director Quality Management Systems
 
Joe has experience implementing ISO 9000-compliant Quality Systems, and CLIA Laboratory-compliant Quality Management System, policies, and procedures. Previously, he held several positions at 454 Life Sciences (a Roche Company), including Group Leader of Software, Manager of Quality Systems, Site Record Manager, and Site Closure Lead. Joe has experience as a software engineer and project/program manager in various business sectors including data communications, telecommunications, medical devices, accounting systems, customer relationship management systems (CRM), and postal solutions.  
 
He has a B.S. in mathematics from UConn and an M.S. in computer science from RPI (Rensselaer at Hartford), and is a certified Project Management Professional (PMP) by the Project Management Institute.